These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

813 related articles for article (PubMed ID: 32699265)

  • 1. Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma.
    Li ZJ; Dai HQ; Huang XW; Feng J; Deng JH; Wang ZX; Yang XM; Liu YJ; Wu Y; Chen PH; Shi H; Wang JG; Zhou J; Lu GD
    Acta Pharmacol Sin; 2021 Feb; 42(2):301-310. PubMed ID: 32699265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic antitumor activity of sorafenib and artesunate in hepatocellular carcinoma cells.
    Yao X; Zhao CR; Yin H; Wang K; Gao JJ
    Acta Pharmacol Sin; 2020 Dec; 41(12):1609-1620. PubMed ID: 32300243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis.
    Li Y; Xia J; Shao F; Zhou Y; Yu J; Wu H; Du J; Ren X
    Biochem Biophys Res Commun; 2021 Jan; 534():877-884. PubMed ID: 33162029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells.
    Zhang Z; Yao Z; Wang L; Ding H; Shao J; Chen A; Zhang F; Zheng S
    Autophagy; 2018; 14(12):2083-2103. PubMed ID: 30081711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
    Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
    Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dihydroartemisinin induces ferroptosis of hepatocellular carcinoma via inhibiting ATF4-xCT pathway.
    Ji J; Cheng Z; Zhang J; Wu J; Xu X; Guo C; Feng J
    J Cell Mol Med; 2024 Apr; 28(8):e18335. PubMed ID: 38652216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DDX39B protects against sorafenib-induced ferroptosis by facilitating the splicing and cytoplasmic export of GPX4 pre-mRNA in hepatocellular carcinoma.
    Li Q; Yuan H; Zhao G; Ou D; Zhang J; Li L; Li S; Feng T; Gu R; Kou Q; Wang Q; Li S; Wang G; Zhao M; Yu H; Qu J; Lin P; Li K
    Biochem Pharmacol; 2024 Jul; 225():116251. PubMed ID: 38701867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tiliroside targets TBK1 to induce ferroptosis and sensitize hepatocellular carcinoma to sorafenib.
    Yang C; Lu T; Liu M; Yuan X; Li D; Zhang J; Zhou L; Xu M
    Phytomedicine; 2023 Mar; 111():154668. PubMed ID: 36657316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma.
    Feng J; Lu PZ; Zhu GZ; Hooi SC; Wu Y; Huang XW; Dai HQ; Chen PH; Li ZJ; Su WJ; Han CY; Ye XP; Peng T; Zhou J; Lu GD
    Acta Pharmacol Sin; 2021 Jan; 42(1):160-170. PubMed ID: 32541921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial GCN5L1 acts as a novel regulator for iron homeostasis to promote sorafenib sensitivity in hepatocellular carcinoma.
    Hu X; Zhang P; Li S; Zhang J; Wang D; Wang Z; Zhu L; Wang L
    J Transl Med; 2024 Jun; 22(1):593. PubMed ID: 38918793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macropinocytosis is an alternative pathway of cysteine acquisition and mitigates sorafenib-induced ferroptosis in hepatocellular carcinoma.
    Byun JK; Lee S; Kang GW; Lee YR; Park SY; Song IS; Yun JW; Lee J; Choi YK; Park KG
    J Exp Clin Cancer Res; 2022 Mar; 41(1):98. PubMed ID: 35287706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SPARC regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma.
    Hua HW; Jiang HS; Jia L; Jia YP; Yao YL; Chen YW; Jiang F; Lu DQ; Zhou Q; Jiang MW; Ding G
    Cancer Biomark; 2021; 32(4):425-433. PubMed ID: 33843664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosome-derived circUPF2 enhances resistance to targeted therapy by redeploying ferroptosis sensitivity in hepatocellular carcinoma.
    Dong FL; Xu ZZ; Wang YQ; Li T; Wang X; Li J
    J Nanobiotechnology; 2024 May; 22(1):298. PubMed ID: 38811968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual GSH-exhausting sorafenib loaded manganese-silica nanodrugs for inducing the ferroptosis of hepatocellular carcinoma cells.
    Tang H; Chen D; Li C; Zheng C; Wu X; Zhang Y; Song Q; Fei W
    Int J Pharm; 2019 Dec; 572():118782. PubMed ID: 31678528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells.
    Louandre C; Marcq I; Bouhlal H; Lachaier E; Godin C; Saidak Z; François C; Chatelain D; Debuysscher V; Barbare JC; Chauffert B; Galmiche A
    Cancer Lett; 2015 Jan; 356(2 Pt B):971-7. PubMed ID: 25444922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effects of α-Mangostin and sorafenib in hepatocellular carcinoma: New insights into α-mangostin cytotoxicity.
    Wang TT; Hong YF; Chen ZH; Wu DH; Li Y; Wu XY; Huang HQ; Zhang Q; Jia CC
    Biochem Biophys Res Commun; 2021 Jun; 558():14-21. PubMed ID: 33894673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein phosphatase 2A-B55β mediated mitochondrial p-GPX4 dephosphorylation promoted sorafenib-induced ferroptosis in hepatocellular carcinoma via regulating p53 retrograde signaling.
    Qian B; Che L; Du ZB; Guo NJ; Wu XM; Yang L; Zheng ZX; Gao YL; Wang MZ; Chen XX; Xu L; Zhou ZJ; Lin YC; Lin ZN
    Theranostics; 2023; 13(12):4288-4302. PubMed ID: 37554285
    [No Abstract]   [Full Text] [Related]  

  • 18. The combination of lonafarnib and sorafenib induces cyclin D1 degradation via ATG3-mediated autophagic flux in hepatocellular carcinoma cells.
    Wang J; Wei H; Huang Y; Chen D; Zeng G; Lian Y; Huang Y
    Aging (Albany NY); 2019 Aug; 11(15):5769-5785. PubMed ID: 31409760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy.
    Liu X; Zhu X; Qi X; Meng X; Xu K
    Int J Nanomedicine; 2021; 16():1037-1050. PubMed ID: 33603367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
    Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
    Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.